Sysmex (OTCMKTS:SSMXY) Trading Down 4.6% – Should You Sell?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) were down 4.6% during trading on Wednesday . The company traded as low as $8.70 and last traded at $8.70. Approximately 200 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 259,757 shares. The stock had previously closed at $9.12.

Analyst Upgrades and Downgrades

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold”.

Sysmex Stock Performance

The stock has a market cap of $5.70 billion, a P/E ratio of 23.83 and a beta of 1.10. The company has a fifty day moving average of $8.74 and a 200 day moving average of $9.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.28%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, equities analysts predict that Sysmex Corporation ADR will post 0.37 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.